ABSCI CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ABSCI CORP (ABSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 1.88 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-11
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 1.46M shares, a 8.43% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 413.35K shares, a 16.84% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 888.34K shares, a 151.04% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 590.64K shares, a 173.51% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 3.18M shares, a 106.30% increase from fiscal 2024.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 1.54M shares, a 61.01% decline from fiscal 2023.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 3.96M shares, a 23.92% increase from fiscal 2022.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 3.19M shares, a 170.03% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.46M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.88M shares 10-Q · filed 2026-08-11 | 2.76M shares derived: sum of 3 quarters · filed 2026-08-11 | 3.36M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 413.35K shares 10-Q · filed 2026-05-07 | 1.30M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.89M shares derived: sum of 3 quarters · filed 2026-05-07 | 3.24M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 888.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 1.48M shares derived: sum of 2 quarters · filed 2026-03-24 | 2.83M shares derived: sum of 3 quarters · filed 2026-03-24 | 3.18M shares 10-K · filed 2026-03-24 |
| 2025-09-30 | 590.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.94M shares derived: sum of 2 quarters · filed 2025-11-12 | 2.29M shares 10-Q · filed 2025-11-12 | 2.65M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.35M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.70M shares 10-Q · filed 2025-08-12 | 2.06M shares derived: sum of 3 quarters · filed 2025-08-12 | 2.27M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 353.79K shares 10-Q · filed 2025-05-13 | 707.65K shares derived: sum of 2 quarters · filed 2025-05-13 | 923.60K shares derived: sum of 3 quarters · filed 2025-05-13 | 1.67M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 353.87K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 569.82K shares derived: sum of 2 quarters · filed 2025-03-18 | 1.32M shares derived: sum of 3 quarters · filed 2025-03-18 | 1.54M shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 215.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 963.58K shares derived: sum of 2 quarters · filed 2024-11-12 | 1.19M shares 10-Q · filed 2024-11-12 | 2.14M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 747.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 972.74K shares 10-Q · filed 2024-08-14 | 1.92M shares derived: sum of 3 quarters · filed 2024-08-14 | 3.53M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 225.11K shares 10-Q · filed 2024-05-14 | 1.17M shares derived: sum of 2 quarters · filed 2024-05-14 | 2.78M shares derived: sum of 3 quarters · filed 2024-05-14 | 3.64M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 946.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 2.56M shares derived: sum of 2 quarters · filed 2024-03-21 | 3.41M shares derived: sum of 3 quarters · filed 2024-03-21 | 3.96M shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 1.61M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 2.46M shares derived: sum of 2 quarters · filed 2023-11-14 | 3.01M shares 10-Q · filed 2023-11-14 | 4.18M shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 853.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 1.40M shares 10-Q · filed 2023-08-14 | 2.57M shares derived: sum of 3 quarters · filed 2023-08-14 | 3.79M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 545.64K shares 10-Q · filed 2023-05-15 | 1.72M shares derived: sum of 2 quarters · filed 2023-05-15 | 2.93M shares derived: sum of 3 quarters · filed 2023-05-15 | 3.46M shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 1.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 2.39M shares derived: sum of 2 quarters · filed 2023-03-30 | 2.91M shares derived: sum of 3 quarters · filed 2023-03-30 | 3.19M shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 1.21M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 1.74M shares derived: sum of 2 quarters · filed 2022-11-09 | 2.02M shares 10-Q · filed 2022-11-09 | 2.58M shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 526.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 806.44K shares 10-Q · filed 2022-08-11 | 1.37M shares derived: sum of 3 quarters · filed 2022-08-11 | 1.62M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 280.05K shares 10-Q · filed 2022-05-11 | 842.89K shares derived: sum of 2 quarters · filed 2022-05-11 | 1.09M shares derived: sum of 3 quarters · filed 2022-05-11 | |
| 2021-12-31 | 562.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | 811.92K shares derived: sum of 2 quarters · filed 2022-03-22 | 1.18M shares 10-K · filed 2022-03-22 | |
| 2021-09-30 | 249.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 619.35K shares 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | 370.26K shares 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |